OPKO Health, Inc. (OPK)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04

$1.64+1.86%

Close 2026-09-04 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Broken: Primary pillar broken — Improve operating income from negative levels: Operating income not reported.

The bull case

OPKO aims for $530M to $560M revenue in 2026. They have new partnerships that may help sales grow. Management wants to improve profit and cut losses. Past beats show some ability to execute.

The bear case

Sales fell in Q1 and earnings missed estimates. Revenue is expected to shrink about 2%. Profit remains negative and losses are large. Meeting revenue targets looks uncertain.

What's priced in

The market expects about 2% revenue decline and continued losses. Our fair value is $7.3, reflecting these challenges. We see risk if revenue falls below guidance.

What has to stay true

Increase gross profit above $45.8MBroken
Management ExecutionsupportingGross profit > $45.8M · next 4 quarters (qualitative)
Breaks if: Gross profit falls below $45.8M
Are they delivering?On Track this quarter· 1 tracked commitment
- Increase gross profitGrowth
  Grow gross profit through higher revenues and improved margins across segments.
  On Track
  Stated as a priority in 2 of last 2 quarters. Gross profit grew from $49.4 million in 2025-Q2 to $80.0 million in 2026-Q2 and from $42.6 million in 2025-Q1 to $45.8 million in 2026-Q1. This indicates delivering progress in increasing gross profit as management has emphasized.

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-04· Version 1· Status: Broken· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

OPK's long-term thesis remains intact amid mixed financial performance and sector support.

What kind of bet this is

This investment represents a turnaround story with a focus on improving operational metrics. The current thesis state is stable, as management is making progress on key priorities despite being loss-making.

What's priced into OPKO Health, Inc. (OPK)

The market appears to have priced in a low expectations gap, suggesting that OPK is viewed as relatively cheap compared to peers. However, there is a low model confidence, indicating uncertainty in future performance.

What the fundamentals likely do

Management is on track to improve operating income and increase gross profit, although they are currently behind on revenue guidance. The near-term risk is moderate, with a low probability of missing expectations, but the company's smaller size adds some volatility.

What OPKO Health, Inc. (OPK) hinges on

The thesis hinges on management's ability to meet revenue targets and the overall performance of the healthcare sector. Key factors include potential guidance cuts and the performance of sector leaders, which could influence OPK's trajectory.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

score change · valuation_score
moderate change
Valuation fell by 21.9 points (from 55.9 to 34.0).

Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Advances in clinical trials for novel therapies could enhance the product pipeline and revenue. Guidance from the recent earnings call confirms progress towards revenue expectations.

as of 2026-09-04

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.